Scarica l'app Stockscreener
10.18
0.20%
0.02
Dopo l'orario di chiusura:
10.31
0.13
+1.28%
Precedente Chiudi:
$10.16
Aprire:
$10.29
Volume 24 ore:
878.37K
Relative Volume:
0.68
Capitalizzazione di mercato:
$778.96M
Reddito:
$31,000
Utile/perdita netta:
$-54.42M
Rapporto P/E:
-10.41
EPS:
-0.9778
Flusso di cassa netto:
$-48.99M
1 W Prestazione:
-7.62%
1M Prestazione:
-22.88%
6M Prestazione:
+103.60%
1 anno Prestazione:
+88.17%
Intervallo 1D:
$10.03
$10.37
Intervallo di 1 settimana:
$10.03
$11.52
Portata 52W:
$4.35
$14.00
Candel Therapeutics Inc Stock (CADL) Company Profile
Nome
Candel Therapeutics Inc
Settore
Industria
Telefono
617-916-5445
Indirizzo
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
10.18 | 843.23M | 31,000 | -54.42M | -48.99M | -0.9778 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-10-28 | Iniziato | Stephens | Overweight |
| 2025-09-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-06-30 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-20 | Iniziato | Citigroup | Buy |
| 2025-02-19 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-07 | Iniziato | BofA Securities | Buy |
| 2022-12-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-08-23 | Iniziato | Credit Suisse | Outperform |
| 2021-08-23 | Iniziato | Jefferies | Buy |
| 2021-08-23 | Iniziato | UBS | Buy |
Mostra tutto
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequ - The Manila Times
Candel Therapeutics NSCLC Trial: 24.5-Month Median Survival | CADL Stock News - Stock Titan
Candel Therapeutics, Inc. (CADL) stock price, news, quote and history - uk.finance.yahoo.com
Candel Therapeutics, Inc. (CADL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer - The Manila Times
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026 - The Manila Times
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
Understanding Momentum Shifts in (CADL) - Stock Traders Daily
Candel Therapeutics (CADL) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
This Small-Cap Biotech Is Having Its Best Week In A Month – Here’s What’s Driving It - Stocktwits
Candel Therapeutics upgraded to Strong Buy afte... - Pluang
Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4 (CADL) - Seeking Alpha
H.C. Wainwright Remains a Buy on Candel Therapeutics (CADL) - The Globe and Mail
Candel Therapeutics stock jumps on BofA upgrade to buy - Investing.com
Candel Therapeutics Shares Rise After BofA Upgrade - Yahoo Finance
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Candel Therapeutics stock jumps on BofA upgrade to buy By Investing.com - Investing.com South Africa
BofA upgrades Candel Therapeutics stock rating on prostate cancer progress - Investing.com
Why is Candel Therapeutics stock surging today? By Investing.com - Investing.com Canada
BofA Securities Upgrades Candel Therapeutics(CADL.US) to Buy Rating, Raises Target Price to $18 - Moomoo
BofA Upgrades Candel Therapeutics to Buy From Neutral, Price Target is $18 - marketscreener.com
Candel Therapeutics Inc (NASDAQ:CADL) Share Price | RNS News, Quotes, & Charts | CADL | - Proactive financial news
Candel Therapeutics at H.C. Wainwright conference: prostate cancer push By Investing.com - Investing.com India
CADL Slides As Form 144 Filing Flags Insider Selling Risk - timothysykes.com
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data - Stocktwits
CADL Slides As Candel Therapeutics Posts Wider Q2 Loss - StocksToTrade
Candel Therapeutics CEO Tak sells $3.16m in CADL stock By Investing.com - Investing.com Australia
Candel Therapeutics CEO Tak sells $3.16m in CADL stock - Investing.com
Candel Therapeutics (NASDAQ: CADL) CEO sells 280K shares under preset plan - Stock Titan
Candel Therapeutics (NASDAQ: CADL) investor plans $3.4M Rule 144 stock sale from equity awards - Stock Titan
Candel Therapeutics at Cantor global healthcare conference: prostate cancer push - Investing.com India
Candel (CADL) gives director options with 36-month vesting - Stock Titan
Candel Therapeutics, Inc. Announces Appointment of Martine Zimmermann to Board of Directors, Effective September 8, 2026 - marketscreener.com
Candel Therapeutics Adds Regulatory Veteran to Board Ahead of Q4 2026 BLA Submission - Minichart
Candel Therapeutics Adds Martine Zimmermann to Board Ahead of Planned BLA Filing - citybiz
Candel Therapeutics appoints Martine Zimmermann to board By Investing.com - Investing.com Canada
Candel Therapeutics appoints Martine Zimmermann to board - investing.com
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors - The Manila Times
CADL 8-K FilingsCandel Therapeutics, Inc. SEC 8-K - Stock Titan
A drug-development expert with 30 years’ experience joins Candel’s board - Stock Titan
CADL Q2 2026 Earnings: Significant EPS Shortfall as Revenue Remains AbsentFiscal Year Earnings - careplusvn.com
BB: BlackBerry Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
(CADL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Candel Therapeutics Stock Price Forecast. Should You Buy CADL? - StockInvest.us
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Show Me The Money: CADL Delivers 190%+ Gain In Less Than Six Months As BLA Filing Nears - RTTNews
Candel Therapeutics stock hits 52-week high at $13.96 By Investing.com - Investing.com South Africa
Candel Therapeutics Inc Azioni (CADL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Candel Therapeutics Inc Azioni (CADL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Tak Paul Peter | Chief Executive Officer |
Sep 10 '26 |
Sale |
11.50 |
220,866 |
2,539,893 |
172,700 |
| Tak Paul Peter | Chief Executive Officer |
Sep 11 '26 |
Sale |
10.46 |
59,379 |
620,891 |
113,321 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):